Kornimate/medical-research-clean huggingface dataset:
emg biofeedback based pelvic floor training in post partum women

Conditions: Urinary Incontinence

Summary: this study intends to determine the effects of electromyographic biofeedback on performance of pelvic floor muscles in urinary incontinence.

this is a single blinded randomized controlled trial ,will be conducted at ripha rehab clinic,rawalpindi. (emg) biofeddback is a adjunct therapy to standard exercise regime for increasing muscle strength,this study is planned to determine the effects of electromyographic biofeedback on performance of pelvic floor muscles, strength,endurance ,rate of biofeedback and its impact on the qulatiy of life (qol).the sample size was calculated to be n=28 through open-epitool version 3 ,with 95%confidence interval (ci),and power 80%. after completion of therapeutic protocols, the participant will be assessed with the help emg-biofeedback, pelvic floor distress inventory, king's health questionnaire.

Eligibility criteria:
inclusion criteria: * post-partum females * persistent urinary leakage at 3 months post-partum period * urine leakage with coughing, sneezing or exercise exclusion criteria: * neurogenic bladder * history of pelvic surgeries, pelvic tumors, uti, urge incontinence, uncontrolled diabetes, cerebral stroke, previous injuries within pelvic

Keywords: pelvic floor muscles electromyographic biofeedback pelvic floor strengthening
hydroxycitrate: a novel therapy for calcium phosphate urinary stones

Conditions: Calcium Phosphate Kidney Stones

Summary: this study tests whether hydroxycitrate, a molecule closely related to citrate, can reduce calcium phosphate stone recurrence.

in this double-blind, placebo-controlled, randomized, crossover study, each participant will undergo 4 phases of study, with the order randomized by a blocked randomization scheme. the 4 phases will be placebo, super citrimax (hydroxycitrate) ohcit low dose, ohcit standard dose, or potassium citrate. randomization will be stratified based on sex, concomitant thiazide use, and concomitant alkali use. each phase will be 1 week in duration, during which subjects will take assigned study medications. a minimum 1-week washout period will be imposed between phases. during the first 2 days of each phase, subjects will be instructed to adhere to a prescribed diet. on the last 5 days of each phase, subjects will be kept on a constant metabolic diet. use of metabolic diet is essential to eliminate confounders that could occur from changes in dietary intake across phases. during the final two study days (days 6-7), two 24-hr urines will be collected for urine biochemistry and crystallization studies. fasting blood will be obtained at the end of the last urine collection. study medications: subjects will receive three tablets twice daily during each phase. these will consist of either placebo, potassium citrate (kcit), or super citrimax (ohcit). study tablets will be prepared by a compounding pharmacy, with placebo tablets similar in appearance and size to the active medication tablets.

Eligibility criteria:
inclusion criteria: - calcium phosphate stone formers exclusion criteria: * history of recurrent urinary tract infections * chronic diarrhea * estimated glomerular filtration rate (egfr) \< 45 ml/min/1.73 m2 * history of primary hyperparathyroidism * hypokalemia * hyperkalemia * pregnancy

Keywords: urolithiasis calcium phosphate citrate acid-base
female sex is an independent predictor of death and bleeding among fibrinolytic treated patients with ami

Conditions: Myocardial Infarction

Summary: this study evaluated differences between men and women in the presentation, management and outcome of heart attacks within the gusto v study.

the global use of strategies to open occluded arteries in acute coronary syndromes (gusto) v trial examined a large, contemporary cohort of women and men with st elevation myocardial infarction (stemi) treated with fibrinolytic therapy. the objective of the present study was to evaluate sex differences in presentation, management and outcome in gusto v.

Eligibility criteria:
inclusion criteria: * inclusion into gusto v exclusion criteria: * lack of availability of data (database study)
diagnosis of bladder outlet obstruction using dynamic urine vibration "holter" in comparison to pressure flow study

Conditions: Bladder Outlet Obstruction

Summary: current gold standard of bladder outlet diagnosis is pressure flow study. this study is invasive time consuming and requires expensive and complex set-up. in this study the investigators plan to evaluate an alternative technology that presumably is able to diagnose bladder outlet obstruction using a dynamic urine vibration "holter" based on a urine flow vibration analysis technology. the acoustic vibration sensor is a small device that records the vibration due to urine flow. the patient attaches the sensor to the penis using a disposable sensor patch for the duration of approximately one minute during one urination. the analysis is performed off-line and the results are compared to the results of a standard pressure flow study. the innovative technology for the diagnosis of bladder outlet obstruction is noninvasive, rapid and does not involve complex setup.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of benign prostatic hyperplasia (bph) * has indication for urodynamic evaluation

Keywords: benign prostatic hyperplasia (bph) acoustic vibration
dose response trial of pergolide for cocaine dependence - 1

Conditions: Cocaine-Related Disorders

Summary: the purpose of this study is to evaluate the efficacy and safety of pergolide for treatment of cocaine dependence.


Eligibility criteria:
please contact site for information.
improve new learning and memory in individuals with mild cognitive impairment

Conditions: Mild Cognitive Impairment

Summary: the current study is a double-blind, placebo-control randomized clinical trial examining the efficacy of memory retraining in individuals with mild cognitive impairment (mci). impairment in higher level cognitive processing, such as new learning and memory, is one of the most common deficits in individuals with mci and such deficits have been shown to exert significant negative impact on multiple aspects of everyday life, including occupational and social functioning. despite these findings, few studies have attempted to treat these cognitive deficits in order to improve the everyday functioning of individuals with mci. through a small randomized clinical trial, the investigators found that individuals with mci with documented cognitive impairment show a significant improvement in their memory performance following a treatment protocol designed to facilitate learning. the current proposal will replicate this finding and further evaluate (a) the impact of the treatment on everyday functioning, (b) the long term efficacy of the treatment and (c) the utility of booster sessions in facilitating long-term treatment effects. we will randomly assign older individuals who meet criteria for a diagnosis of amnestic mci to a memory retraining group or a placebo control group. both groups will undergo baseline, immediate and long-term follow-up assessment consisting of: (1) a traditional neuropsychological battery, (2) an assessment of global functioning examining the impact of the treatment on daily activities, and (3) functional neuroimaging. this design will allow the investigators to evaluate the efficacy of this particular memory retraining technique in an amci population through the assessment of cognitive function via a standard evaluation. in addition, the investigators will be able to draw conclusions regarding the impact of this particular memory remediation program on everyday life from questionnaires completed by the participant and a significant other. optional enrollment in pre- post neuroimaging will also allow the investigators to look at changes in the brain.


Eligibility criteria:
inclusion criteria: * 60 or older. * read and speak english fluently. * research based diagnosis of amnestic mild cognitive impairment exclusion criteria: * prior stroke or neurological injury/disease (i.e. traumatic brain injury, multiple sclerosis, or stroke). * history of significant psychiatric illness (for example, bipolar disorder, schizophrenia, or psychosis). * significant alcohol or drug abuse history (inpatient treatment). * benzodiazepines and steroid use

Keywords: memory learning rehabilitation aging cognition
facet wedge post market study

Conditions: Chronic Low Back Pain; Degenerative Disc Disease; Facet Joint Disease; Pseudo Arthrosis Post Anterior Instrumentation

Summary: a multi-centre, prospective, single-arm post market clinical follow up study (pmcf) of the facet wedgetm spinal system to assess outcomes in subjects with chronic low back pain due to degenerative disc disease (ddd), facet joint disease and/or pseudo arthrosis post anterior instrumentation. the objective of this study is to assess outcomes following implantation of the facet wedge spinal system when used to provide fixation of lumbar motion segments. the primary objective of this study is to determine the rate of re-operations at the index level(s). the secondary objectives of this study are to confirm the safety and performance of the device and to collect patient reported outcome data.


Eligibility criteria:
inclusion criteria: 1. subjects diagnosed with at least one of the following: * degenerative disc disease (ddd); * degenerative facet joint disease (isolated facet based symptomatic back pain); * pseudoarthrosis post anterior instrumentation; 2. subjects who are a fusion candidate for single or multiple levels fusion between l1-s1; 3. subjects, who, in the opinion of the investigator, are able to understand this clinical investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups. exclusion criteria: preoperative exclusion criteria: 1. segmental instability of the index level in case of planned stand-alone facet wedge usage; 2. unilateral application , except in combination with pediclescrew fixation on the contralateral side; 3. compromised facets due to decompression techniques; 4. spondylolisthesis; 5. fracture or other instabilities of the posterior elements; 6. tumor; 7. acute or chronic systemic or localized spinal infections; 8. nursing mothers or women who are pregnant or plan to become pregnant during the time of the study; 9. subjects aged below 18 years; 10. subjects who, in the opinion of the investigator, have an existing condition that would compromise their participation and follow-up in this clinical investigation; intraoperative exclusion criteria: 11. intraoperative decision to use implants other than the device under investigation.
fundus camera module for early detection of alzheimer's disease

Conditions: Alzheimer Disease

Summary: alzheimer's disease (ad) affects tens of millions of people just in europe. it is typically detected in its late stage when irreversible damage has already occurred, and current treatments are mostly conservative or palliative. here we developed a device performing high-resolution multispectral imaging of the eye fundus to detect ad in its early stage. after clinical testing, the proposed device has a high potential to become a method for routine population screening, as it is non-invasive and affordable. the possibility of ad detection in an early stage is crucial for developing a new pharmaceutical treatment that would dramatically improve the lives of millions and save the expenses connected to lifelong healthcare assistance to people with ad in later stages.


Eligibility criteria:
inclusion criteria: * 55 years or older * diagnosis: 1. for ad group: clinically diagnosed with alzheimer's disease (mild to moderate stage) based on mini-mental state examination (mmse) score between 10-26 and confirmed by pet imaging or csf. 2. for control group: no diagnosis of alzheimer's disease or other neurodegenerative disorders. * signed informed consent by the patient. if there are any doubts that the patient is mentally capable of giving informed consent, the patient will be examined and verified to be mentally capable by an independent physician/ neurologist, prior to the initiation of any study specific procedure exclusion criteria: * severe cognitive impairment (mmse \<10) preventing cooperation during the imaging process. * inability to remain still during the fundus imaging procedure.
treatment of impetigo with topical sb-275833 ointment, 1% versus topical placebo ointment

Conditions: Impetigo

Summary: the goal of this study is to determine if topical sb-275833 ointment, 1% is more effective than a placebo ointment in the treatment of primary impetigo.


Eligibility criteria:
inclusion criteria: * must have primary impetigo with total lesion area being 100 square centimeters or less. * women who could bear children must have a negative urine pregnancy test and agree to either abstain from sexual intercourse or the use of specific effective contraceptive measures. exclusion criteria: * any signs and symptoms of systemic infection. * any serious underlying disease that could be imminently life threatening.

Keywords: impetigo topical antibacterial topical antibiotic
sex differences in sympathetic activity and vascular reactivity during acute and chronic hypoxia.

Conditions: Vasodilation; Vasoconstriction

Summary: this study aims to investigate sex differences in blood pressure control associated with exposure to acute hypoxia (low oxygen), and short term acclimatization to hypoxia at high altitude.

about 200 million people worldwide live at high altitudes. millions of others travel to high altitude every year for work or travel. the low oxygen (or hypoxia) experienced at high altitudes causes considerable physiological stress, and the body adapts in order to maintain adequate oxygen delivery to its tissues. one of these adaptations is an increase in the activity of the sympathetic nervous system. this system is responsible for the "fight or flight" response. sympathetic activity regulates the size of the blood vessels, which will affect blood pressure. previous studies suggest that males and females regulate their blood pressure in different ways. females tend to have lower resting sympathetic activity, and less vasoconstriction in response to stressors than males. blood pressure changes are also influenced by levels of sex hormones; for example, estrogen may cause opposing vasodilation. therefore, it is important to understand the differences in how males and females respond to low oxygen. the main purpose of this study is to examine the differences between males and females in control of blood vessels during exposure to low oxygen. to study this question, we will test vasoreactivity to set physiological stressors in both males and females. participants will be recruited at the canadian sites, and we will test them while they breathe low oxygen for a short amount of time at low altitude. we will also perform assessments on the same participants during a two week stay at high altitude at white mountain, ca, which is at an altitude of 3,800m. these data will have implications in the basic understanding of differences between male and female physiology. specifically, to males and females living or travelling to high altitude.

Eligibility criteria:
inclusion criteria: * between ages of 18-50 * no medical history of cardiovascular, respiratory, nervous system, or metabolic disease * females must be pre-menopausal exclusion criteria: * any known cardiovascular, respiratory, nervous system, or metabolic disease (however, participants with controlled arterial hypertension will not be excluded) * having travelled above 2,000m within 1 month of testing at low and high altitude * females who are pregnant, confirmed by a pregnancy test * females who are post-menopausal * participants that are classified as obese (body mass index \> 30kg⋅m²) * have a history of smoking regularly in the last 6 months (but nicotine substitutes (patch, gum) not an exclusion criteria) * those with a known allergy to sulfites * participants taking monoamine oxidase (mao) inhibitors or tricyclic antidepressants
pilot study to evaluate ear acupressure effects in treating seasonal allergic rhinitis

Conditions: Seasonal Allergic Rhinitis

Summary: we hypothesize that ear acupressure will be effective in treating seasonal allergic rhinitis by changing the immune parameters and the psychological impact factors are associated with ear acupressure treatment outcome.

the purpose of the study is to investigate the clinical potential of ear acupressure in treating seasonal allergic rhinitis. we hypothesize that ear acupressure will be effective in treating seasonal allergic rhinitis by changing the immune parameters and the psychological impact factors such as expectation, stress, depression, and anxiety can moderate the ear acupressure treatment effectiveness in allergic rhinitis by influencing the immune parameters.

Eligibility criteria:
inclusion criteria: * seasonal allergic rhinitis was diagnosed both by history and clinical examination and by the presence at positive skin prick tests * all participants need to have at least 2 years of seasonal allergic rhinitis symptoms and a positive skin prick test to one or more pollen allergens exclusion criteria: * use of systemic corticosteroids within past 3 months period, * active asthma, * hearing aid usage, * history of adhesive tape allergy, * history of metal allergy, * hiv, * hepatitis b or c, * history of hematologic, autoimmune, or malignant disease, * pregnancy or lactation, * ear acupressure (eap) or acupuncture for respiratory disease within the last 6 months

Keywords: hay fever hayfever pollen allergy pollinosis seasonal allergic rhinitis
a study to assess relatlimab and nivolumab fixed-dose combination in chinese participants with advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: the purpose of this study is to assess the safety, drug levels, immunogenicity and preliminary efficacy of bms-986213 (nivolumab-relatlimab fixed-dose combination) in chinese participants with advanced solid tumors.


Eligibility criteria:
inclusion criteria: * presence of at least one lesion with measurable disease as defined by recist v1.1 criteria for response assessment * participants must have received, and then progressed, or been intolerant to at least one standard treatment regimen in the advanced or metastatic setting, if such a therapy exists * ecog status of 0 or 1 * life expectancy of ≥ 12 weeks at the time of informed consent per investigator assessment exclusion criteria: * participants with history of severe and/or life-threatening toxicity related to prior immune therapy (eg, anti-ctla-4 or anti-pd-1/pd-l1 treatment or any other antibody or drug specifically targeting t-cell co-stimulation or immune checkpoint pathways) * participants with an active, known or suspected autoimmune disease * participants with primary cns tumors other protocol-defined inclusion/exclusion criteria apply

Keywords: bms-986213
a randomised control trial of a transitional care model in singapore general hospital

Conditions: Chronic Diseases

Summary: to find out if a transitional care model can reduce the rate of unscheduled readmission to the department of internal medicine (dim) in sgh

hospital with high readmission rate is view as having lower quality of care high readmission rate is view as wasteful healthcare spending primary aim: to find out if a transitional care model can reduce the rate of unscheduled readmission to the department of internal medicine (dim) in sgh a readmission episode is defined as an episode of readmission to any tertiary hospital within 30 days after index discharge from sgh secondary aim: to find out if a transitional care model can reduce the number of visits to the emergency department in sgh to find out the quality of our transitional care model by using a care transition measure (ctm-15)

Eligibility criteria:
inclusion criteria -more than 1 admission in the last 90 days exclusion criteria * subject is a non-resident * subject has no local home address * subject is from a long-term care facility during index admission * subject is unable to participate in telephone surveillance * subject is discharged before takeover * subject has impaired decision making capacity without surrogate decision maker * subject is pending or currently in critical care unit * subject or caregiver is mentally unstable * subject is haemodynamically unstable * subject requires acute inpatient respiratory support * subject requires acute inpatient dialysis support * subject pending surgical intervention * subject pending transfer to other specialist discipline * primary team consultant declined to participate in this research

Keywords: readmission care transition
5-htp in patients with ibd in clinical and biologic remission:effect on fatigue scores

Conditions: Crohn Disease; Ulcerative Colitis; Fatigue; Remission

Summary: this placebo cross-over trial aims to study the effect of the oral intake of an essential amino-acid 5-oh tryptophan, the precursor of serotonin, on the fatigue scores in ibd patients in deep clinical and biological remission.


Eligibility criteria:
inclusion criteria: * the subject is male or female and aged 18 to 60 yrs (inclusive) * the subject has a documented crohn's disease or ulcerative colitis * the subject is, in the opinion of the investigator, capable of understanding and complying protocol requirements * the subject is in clinical remission over last 3 months (based on physician global assessment) * the subject is in clinical remission at day 0 based on validated scores (sccai ≤ 2 for ulcerative colitis or harvey bradshaw index ≤ 4 for crohn's disease). * the subject reports fatigue on a quantified scale (visual analogue scale 0 - 10) of 5 or more * the subject is treated with biologicals and/or immunosuppressives since at least 6 months with stable dose over last 3 months * the subject is in biologic remission at day 0: crp \< 10 mg/l and faecal calprotectin value \< 250 mg/kg exclusion criteria: * the subject has a clinical validated depression * the subject is taking antidepressives or neuroleptics * the subject has a psychiatric comorbidity * the subject has important comorbidities: cardiovascular disease, obstructive lung pathology, neoplasia or other * the subject has a documented anemia (based on lab results including hb \< 12-13 g/dl respectively for saturation index \< 20%, vit b12 \< 148 pmol/l or folic acid \< 6 nmol/l) * the subject has a documented hypothyreoidea (documented by a recent lab result including tsh) * the subject reports an infection within 2 weeks before inclusion * the subject reports any change in ibd medication (biologicals and immunosuppressives) in the last 12 weeks before inclusion * the subject was treated with oral corticosteroids during the last 8 weeks before enrolment * the subject reports an ongoing pregnancy or breastfeeding * the subject has a history of lymphoproliferative disease or cancer other than basocellular skin cancer * the subject underwent surgery in the past 12 weeks prior to the screening visit * the subject reports a history of clinically significant drug abuse (defined as any illicit drug use) or alcohol abuse within 1 year prior to inclusion